Sydney, Australia – 31 October 2025 – Southern Star Research (SSR) has been recognised with two major honours at the 2025 NSW Export Awards — taking home both the NSW Exporter of the Year and International Health Award titles. These achievements highlight the company’s growing global presence and continued contribution to advancing healthcare through world-class clinical research.
The NSW Export Awards, presented by the Export Council of Australia, celebrate businesses that demonstrate excellence in international trade and showcase the state’s innovation and capability on the global stage.
Dianne Tipping, Chair of the Export Council of Australia, congratulated all winners and acknowledged the important role of organisations like Southern Star Research in strengthening Australia’s reputation for quality and innovation.
Lloyd Prescott, CEO of Southern Star Research, said:
“We are deeply honoured to receive these awards. This recognition is a testament to the dedication of our team and our unwavering commitment to advancing global health through high-quality clinical research.”
David Lloyd, Managing Founder of Southern Star Research, added:
“As a proud NSW-based organisation, we are passionate about highlighting the strength of local talent and demonstrating our ability to have global impact. This acknowledgement reinforces our mission to deliver excellence in healthcare outcomes while contributing meaningfully to the growth of NSW’s export economy.”
For more than 15 years, Southern Star Research’s highly qualified clinical team has supported trials across a wide range of therapeutic areas — from common to complex indications. This experience ensures that clinical trials benefit from insights developed across diverse patient populations and clinical challenges.
Southern Star Research looks forward to celebrating at the National Export Awards ceremony on 26 November in Canberra, where the 14 category winners will be announced, and one will also be named Australian Exporter of the Year.
At Southern Star Research, we empower small and mid-sized biotech, pharmaceutical, and medical device companies to confidently navigate complex early-phase clinical development across APAC. As Australia’s trusted, independent mid-sized CRO, we offer the “sweet spot” advantage: substantial enough to provide comprehensive, globally recognized services, yet agile and client-focused for truly personalized engagement. While our core strength lies in
Phase I and II trials, our proven experience and robust infrastructure ensure seamless progression into Phase III when your program demands it
Simi Barretto
Marketing and Digital Media Manager
Southern Star Research
Location: Australia
Email: media@southernstarresearch.com
Tel: +61283501918
L1, 1 Merriwa Street,
Gordon, NSW, 2072 Australia
Connect with us
Keep up to date with the latest news, updates and promotions
"*" indicates required fields
Southern Star Research values your privacy and is committed to protecting your personal information. We’ll only use your details for essential communications related to your account. From time to time, we’d like to share updates about our latest news, research, and other content that may interest you.
By clicking 'SUBSCRIBE NOW', you agree that Southern Star Research may collect and use your personal data for these marketing and communication purposes.
Each member of our Leadership Team boasts an average of 30 years experience. Our clients have access to an extraordinary group of Clinical Research professionals, whose experience covers Multinational Pharmaceutical companies, Biotechnology, Medical Device, CRO’s, research institutes, Universities, Industry Associations & Government Bodies. Together, we ensure that every aspect of your unique and novel drug study clinical trial is handled with scientific precision, care, and foresight.
Our team has all of the tools, knowledge and experience to solve almost any issue that may arise during the complex clinical trial process.
We recognize that each study is unique and different and there are nuances that need to be resolved proactively.
Our advisory board of top-tier specialists in multiple therapeutic areas engage in the early stages from protocol design in constructive discussions to anticipate challenges and enhance study efficiency throughout the study.